Cancer screening in older adults: What to do when we don't know

Journal of Geriatric Oncology

Volumn 2, Issue 3, 2011, Pages 149-160

  Alibhai, Shabbir M H ^a,b,c,d   Horgan, Anne M ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Societe canadienne du cancer   (Canada)

Author keywords

Aged; Cancer screening; Mass screening

Indexed keywords

AGE; BREAST CANCER; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MAMMOGRAPHY; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVIEW; UTERINE CERVIX CANCER;

EID: 79958703775     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2011.03.004     Document Type: Review

References (108)

1. Kinsella K., Velkoff V.A. An aging world: 2001. U.S. Census Bureau P95/01-1 2001, U.S. Government Printing Office, Washington (DC).
2. SEER Cancer Statistics Review, 1975-2000 2003, National Cancer Institute, Bethesda, MD. L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, L. Clegg (Eds.).
3. Sawaya G.F., Brown A.D., Washington A.E., Garber A.M. Clinical practice. Current approaches to cervical-cancer screening. N. Engl. J. Med. 2001, 344:1603-1607.
4. Jerant A.F., Franks P., Jackson J.E., Doescher M.P. Age-related disparities in cancer screening: analysis of 2001 Behavioral Risk Factor Surveillance System data. Ann. Fam. Med. 2004, 2:481-487.
5. Bynum J.P., Braunstein J.B., Sharkey P., Haddad K., Wu A.W. The influence of health status, age, and race on screening mammography in elderly women. Arch. Intern. Med. 2005, 165:2083-2088.
6. Canadian Cancer Society: Canadian Cancer Statistics 2010. Toronto, 2010.
7. Humphrey L.L., Helfand M., Chan B.K., Woolf S.H. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2002, 137:347-360.
8. Kerlikowske K., Grady D., Rubin S.M., Sandrock C., Ernster V.L. Efficacy of screening mammography. A meta-analysis. JAMA 1995, 273:149-154.
9. Thomas D.B., Gao D.L., Ray R.M., Wang W.W., Allison C.J., Chen F.L., et al. Randomized trial of breast self-examination in Shanghai: final results. J. Natl. Cancer Inst. 2002, 94:1445-1457.
10. Baxter N. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer?. Cmaj 2001, 164:1837-1846.
11. Chiarelli A.M., Majpruz V., Brown P., Theriault M., Shumak R., Mai V. The contribution of clinical breast examination to the accuracy of breast screening. J. Natl. Cancer Inst. 2009, 101:1236-1243.
12. Kerlikowske K., Grady D., Barclay J., Sickles E.A., Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996, 276:33-38.
13. Schonberg M.A., Silliman R.A., Marcantonio E.R. Weighing the benefits and burdens of mammography screening among women age 80 years or older. J. Clin. Oncol. 2009, 27:1774-1780.
14. Kerlikowske K., Salzmann P., Phillips K.A., Cauley J.A., Cummings S.R. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA 1999, 282:2156-2163.
15. Kerlikowske K., Grady D., Barclay J., Sickles E.A., Eaton A., Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 1993, 270:2444-2450.
16. Nystrom L., Andersson I., Bjurstam N., Frisell J., Nordenskjold B., Rutqvist L.E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359:909-919.
17. Tabar L., Vitak B., Chen H.H., Duffy S.W., Yen M.F., Chiang C.F., et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol. Clin. North Am. 2000, 38:625-651.
18. Mandelblatt J.S., Cronin K.A., Bailey S., Berry D.A., de Koning H.J., Draisma G., et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann. Intern. Med. 2009, 151:738-747.
19. Mandelblatt J., Saha S., Teutsch S., Hoerger T., Siu A.L., Atkins D., et al. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2003, 139:835-842.
20. Ernster V.L., Ballard-Barbash R., Barlow W.E., Zheng Y., Weaver D.L., Cutter G., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J. Natl. Cancer Inst. 2002, 94:1546-1554.
21. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
22. Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Cmaj 2001, 164:1017-1025.
23. ACS-CFFA. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf.
24. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 2002, 52:342-362.
25. Brawley O.W., Kramer B.S. Cancer screening in theory and in practice. J. Clin. Oncol. 2005, 23:293-300.
26. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 2006, 119:1095-1101.
27. Koliopoulos G., Arbyn M., Martin-Hirsch P., Kyrgiou M., Prendiville W., Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol. Oncol. 2007, 104:232-246.
28. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 2007, 357:1579-1588.
29. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362:1871-1876.
30. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl. Cancer Inst. 2004, 96:280-293.
31. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010, 11:249-257.
32. Cervical Cancer Screening in Canada: 1998 Surveillance Report 1998, Public Health Agency of Canada, Ottawa.
33. Mandelblatt J.S., Hammond D.B. Primary care of elderly women: is Pap smear screening necessary?. Mt. Sinai J. Med. 1985, 52:284-290.
34. Ostbye T., Greenberg G.N., Taylor D.H., Lee A.M. Screening mammography and Pap tests among older American women 1996-2000: results from the Health and Retirement Study (HRS) and Asset and Health Dynamics Among the Oldest Old (AHEAD). Ann. Fam. Med. 2003, 1:209-217.
35. Stenkvist B., Bergstrom R., Eklund G., Fox C.H. Papanicolaou smear screening and cervical cancer. What can you expect?. JAMA 1984, 252:1423-1426.
36. Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002, 287:2372-2381.
37. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N. Engl. J. Med. 1993, 328:1365-1371.
38. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348:1467-1471.
39. Hardcastle J.D., Chamberlain J.O., Robinson M.H., Moss S.M., Amar S.S., Balfour T.W., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472-1477.
40. Faivre J., Dancourt V., Lejeune C., Tazi M.A., Lamour J., Gerard D., et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004, 126:1674-1680.
41. Walsh J.M., Terdiman J.P. Colorectal cancer screening: scientific review. JAMA 2003, 289:1288-1296.
42. Thiis-Evensen E., Hoff G.S., Sauar J., Langmark F., Majak B.M., Vatn M.H. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand. J. Gastroenterol. 1999, 34:414-420.
43. Hoff G., Grotmol T., Skovlund E., Bretthauer M. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009, 338:b1846.
44. Atkin W.S., Edwards R., Kralj-Hans I., Wooldrage K., Hart A.R., Northover J.M., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633.
45. Prorok P.C., Andriole G.L., Bresalier R.S., Buys S.S., Chia D., Crawford E.D., et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control. Clin. Trials 2000, 21:273S-309S.
46. Winawer S.J., Zauber A.G., Ho M.N., O'Brien M.J., Gottlieb L.S., Sternberg S.S., et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N. Engl. J. Med. 1993, 329:1977-1981.
47. Citarda F., Tomaselli G., Capocaccia R., Barcherini S., Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001, 48:812-815.
48. Imperiale T.F., Wagner D.R., Lin C.Y., Larkin G.N., Rogge J.D., Ransohoff D.F. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N. Engl. J. Med. 2000, 343:169-174.
49. Lieberman D.A., De Garmo P.L., Fleischer D.E., Eisen G.M., Helfand M. Patterns of endoscopy use in the United States. Gastroenterology 2000, 118:619-624.
50. Baxter N.N., Goldwasser M.A., Paszat L.F., Saskin R., Urbach D.R., Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann. Intern. Med. 2009, 150:1-8.
51. Brenner H., Hoffmeister M., Arndt V., Stegmaier C., Altenhofen L., Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J. Natl. Cancer Inst. 2010, 102:89-95.
52. Sonnenberg A., Delco F., Inadomi J.M. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann. Intern. Med. 2000, 133:573-584.
53. Winnan G., Berci G., Panish J., Talbot T.M., Overholt B.F., McCallum R.W. Superiority of the flexible to the rigid sigmoidoscope in routine proctosigmoidoscopy. N. Engl. J. Med. 1980, 302:1011-1012.
54. Nelson D.B., McQuaid K.R., Bond J.H., Lieberman D.A., Weiss D.G., Johnston T.K. Procedural success and complications of large-scale screening colonoscopy. Gastrointest. Endosc. 2002, 55:307-314.
55. Pickhardt P.J. Incidence of colonic perforation at CT colonography: review of existing data and implications for screening of asymptomatic adults. Radiology 2006, 239:313-316.
56. Warren J.L., Klabunde C.N., Mariotto A.B., Meekins A., Topor M., Brown M.L., et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann. Intern. Med. 2009, 150:849-857. W152.
57. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2008, 149:627-637.
58. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J. Natl. Cancer Inst. 2002, 94:981-990.
59. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 2005, 352:1977-1984.
60. Alibhai S.M., Klotz L.H. A systematic review of randomized trials in localized prostate cancer. Can. J. Urol. 2004, 11:2110-2117.
61. Andriole G.L., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009, 360:1310-1319.
62. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009, 360:1320-1328.
63. Barry M.J. Screening for prostate cancer-the controversy that refuses to die. N. Engl. J. Med. 2009, 360:1351-1354.
64. Wolf A.M., Wender R.C., Etzioni R.B., Thompson I.M., D'Amico A.V., Volk R.J., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 2010, 60:70-98.
65. Hoogendam A., Buntinx F., de Vet H.C. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam. Pract. 1999, 16:621-626.
66. Harris R., Lohr K.N. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2002, 137:917-929.
67. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005, 294:66-70.
68. Draisma G., Boer R., Otto S.J., van der Cruijsen I.W., Damhuis R.A., Schroder F.H., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 2003, 95:868-878.
69. Tornblom M., Eriksson H., Franzen S., Gustafsson O., Lilja H., Norming U., et al. Lead time associated with screening for prostate cancer. Int. J. Cancer 2004, 108:122-129.
70. Frankel S., Smith G.D., Donovan J., Neal D. Screening for prostate cancer. Lancet 2003, 361:1122-1128.
71. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2008, 149:185-191.
72. Smith R.A., Cokkinides V., Eyre H.J. American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J. Clin. 2005, 55:31-44. quiz 55-36.
73. Albertsen P.C., Fryback D.G., Storer B.E., Kolon F., Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J. Urol. 1996, 156:127-132.
74. Piccirillo J.F., Tierney R.M., Costas I., Grove L., Spitznagel E.L. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291:2441-2447.
75. Walter L.C., Covinsky K.E. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001, 285:2750-2756.
76. Fried L.P., Kronmal R.A., Newman A.B., Bild D.E., Mittelmark M.B., Polak J.F., et al. Risk factors for 5-year mortality in older adults. JAMA 1998, 279:585-592.
77. Ganguli M., Dodge H.H., Mulsant B.H. Rates and predictors of mortality in an aging, rural, community-based cohort: the role of depression. Arch. Gen. Psychiatry 2002, 59:1046-1052.
78. Walter L.C., Brand R.J., Counsell S.R., Palmer R.M., Landefeld C.S., Fortinsky R.H., et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA 2001, 285:2987-2994.
79. Walter L.C., Lindquist K., Nugent S., Schult T., Lee S.J., Casadei M.A., et al. Impact of age and comorbidity on colorectal cancer screening among older veterans. Ann. Intern. Med. 2009, 150:465-473.
80. Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006, 295:801-808.
81. National Center for Health Statistics. Life Tables of the United States. In; 1997.
82. Autier P., Hery C., Haukka J., Boniol M., Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J. Clin. Oncol. 2009, 27:5919-5923.
83. Gotzsche P.C., Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 2006, CD001877.
84. Andersson I., Nystrom L. Mammography screening. J. Natl. Cancer Inst. 1995, 87:1263-1264.
85. Bjurstam N., Bjorneld L., Warwick J., Sala E., Duffy S.W., Nystrom L., et al. The Gothenburg Breast Screening Trial. Cancer 2003, 97:2387-2396.
86. Moss S.M., Cuckle H., Evans A., Johns L., Waller M., Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006, 368:2053-2060.
87. Miller A.B., To T., Baines C.J., Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann. Intern. Med. 2002, 137:305-312.
88. Miller A.B., To T., Baines C.J., Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J. Natl. Cancer Inst. 2000, 92:1490-1499.
89. Roberts M.M., Alexander F.E., Anderson T.J., Chetty U., Donnan P.T., Forrest P., et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 1990, 335:241-246.
90. Kosters J.P., Gotzsche P.C. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst. Rev. 2003, CD003373.
91. Screening for breast cancer recommendations and rationale. Ann. Intern. Med. 2002, 137:344-346.
92. Semiglazov V.F., Moiseenko V.M., Manikhas A.G., Protsenko S.A., Kharikova R.S., Popova R.T., et al. Role of breast self-examination in early detection of breast cancer: Russia/WHO prospective randomized trial in St. Petersburg. Cancer Strategy 1999, 1:145-151.
93. Pisani P., Parkin D.M., Ngelangel C., Esteban D., Gibson L., Munson M., et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int. J. Cancer 2006, 118:149-154.
94. NCICcrAa. http://cancercontrol.cancer.gov/grants/abstract.asp?applid=6965060.
95. Boulos S., Gadallah M., Neguib S., Essam E., Youssef A., Costa A., et al. Breast screening in the emerging world: high prevalence of breast cancer in Cairo. Breast 2005, 14:340-346.
96. Atkin W., Kralj-Hans I., Wardle J., Duffy S. Colorectal cancer screening. Randomised trials of flexible sigmoidoscopy. BMJ 2010, 341:c4618.
97. Gatto N.M., Frucht H., Sundararajan V., Jacobson J.S., Grann V.R., Neugut A.I. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J. Natl. Cancer Inst. 2003, 95:230-236.
98. Saito H., Soma Y., Koeda J., Wada T., Kawaguchi H., Sobue T., et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int. J. Cancer 1995, 61:465-469.
99. Saito H., Soma Y., Nakajima M., Koeda J., Kawaguchi H., Kakizaki R., et al. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Oncol. Rep. 2000, 7:815-819.
100. http://clinicaltrials.gov/ct2/results?term=NCT00906997.
101. http://www.clinicaltrials.gov/ct2/results?term=NCT00883792.
102. Whitlock E.P., Lin J.S., Liles E., Beil T.L., Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2008, 149:638-658.
103. Muller A.D., Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch. Intern. Med. 1995, 155:1741-1748.
104. Levin T.R., Zhao W., Conell C., Seeff L.C., Manninen D.L., Shapiro J.A., et al. Complications of colonoscopy in an integrated health care delivery system. Ann. Intern. Med. 2006, 145:880-886.
105. Rabeneck L., Paszat L.F., Hilsden R.J., Saskin R., Leddin D., Grunfeld E., et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008, 135:1899-1906. 1906 e1891.
106. Arora G., Mannalithara A., Singh G., Gerson L.B., Triadafilopoulos G. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest. Endosc. 2009, 69:654-664.
107. Lin O.S., Kozarek R.A., Schembre D.B., Ayub K., Gluck M., Drennan F., et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. JAMA 2006, 295:2357-2365.
108. http://clinicaltrials.gov/ct2/results?term=NCT01200303.